Welcome to your daily round-up of everything happening in the world of neurorehab.
Research
Midlife stress may be risk factor for Alzheimer’s
Stressful experiences in midlife or during childhood may be associated with a higher risk of developing Alzheimer’s disease and neuroinflammation, according to a new study published in Annals of Neurology and led by the Barcelona Institute for Global Health (ISGlobal).
Antioxidant supplement improves cognition in early studies
A new study has found that mice administered with a blended antioxidant supplement show significant improvements in spatial cognition, short-term memory, and mitigated age-related muscle decline. The study suggests that these supplements hold promise as a dietary intervention for health issues associated with ageing.
Study finds improvements from stem cell therapy after spinal cord injury
A Mayo Clinic study shows stem cells derived from patients’ own fat are safe and may improve sensation and movement after traumatic spinal cord injuries.The results of this early research offer insights on the potential of cell therapy for people living with spinal cord injuries and paralysis for whom options to improve function are extremely limited.
Skin test detects evidence of Parkinson’s
A study showed that a simple skin biopsy could identify people who had Parkinson’s disease or similar disorders with a high degree of accuracy. The findings could lead to earlier, more accurate diagnosis of the neurodegenerative conditions known as synucleinopathies.
$20k prize for stroke research
The Global Cardiovascular Research Funders Forum is inviting scientific researchers to compete in a new data challenge, which aims to identify gaps in research funding for cardiovascular and stroke science. Hosted on the American Heart Association’s Precision Medicine Platform, the winning project is eligible to receive a $20,000 USD cash prize.
Policy news
NICE launches second consultation on genetic testing to guide stroke treatment
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes. A second consultation on recommendations that clinicians should offer CYP2C19 genotype testing when considering treatment with clopidogrel after an ischaemic stroke or Transient Ischaemic Attack (a ‘mini stroke’) was launched by NICE on Wednesday (3 April).
Company updates
Neurosterix to accelerate new therapeutics for neurological disorders
Addex Therapeutics, with funds affiliated with Perceptive Advisors, has launched Neurosterix, a new company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
Asha Therapeutics announces new candidate for ALS
Asha Therapeutics has announced the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.
